Published in Microbes Infect on November 01, 2008
Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol (2009) 1.69
Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog (2009) 1.53
Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun (2009) 1.46
Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect Immun (2009) 1.24
Urothelial signaling. Auton Neurosci (2009) 1.22
How to make it in the urinary tract: a tutorial by Escherichia coli. PLoS Pathog (2012) 0.85
From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections. Curr Urol Rep (2013) 0.84
Novel Strategies in the Prevention and Treatment of Urinary Tract Infections. Pathogens (2016) 0.83
Involvement of Src in the Adaptation of Cancer Cells under Microenvironmental Stresses. J Signal Transduct (2012) 0.81
Glycosylation of uroplakins. Implications for bladder physiopathology. Glycoconj J (2014) 0.80
A Murine Model for Escherichia coli Urinary Tract Infection. Methods Mol Biol (2016) 0.77
Membrane microdomain-associated uroplakin IIIa contributes to Src-dependent mechanisms of anti-apoptotic proliferation in human bladder carcinoma cells. Biol Open (2012) 0.76
LIPOPOLYSACCHARIDE DOMAINS MODULATE UROVIRULENCE. Infect Immun (2016) 0.75
Role of renal urothelium in the development and progression of kidney disease. Pediatr Nephrol (2016) 0.75
Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science (1998) 8.16
Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun (2001) 4.82
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (1997) 4.57
The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell (1982) 4.17
Bacterial adhesion to target cells enhanced by shear force. Cell (2002) 3.98
Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli. Infect Immun (1986) 2.65
Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am (2003) 2.47
In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci U S A (1996) 2.35
Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem (2001) 2.34
Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci (2001) 2.13
Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem (1994) 2.07
Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB. Infect Immun (2001) 1.66
Escherichia coli CdtB mediates cytolethal distending toxin cell cycle arrest. Infect Immun (2001) 1.56
Molecular cloning of a 47 kDa tissue-specific and differentiation-dependent urothelial cell surface glycoprotein. J Cell Sci (1993) 1.56
Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J (2005) 1.45
Induction of urinary tract infection by intraurethral inoculation with Escherichia coli: refining the murine model. J Infect Dis (1995) 1.43
Specific heterodimer formation is a prerequisite for uroplakins to exit from the endoplasmic reticulum. Mol Biol Cell (2002) 1.33
Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol (1999) 1.32
Antigen-specific responses accelerate bacterial clearance in the bladder. J Immunol (2006) 1.32
Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci (2004) 1.29
Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect Immun (2006) 1.15
Molecular identification and characterization of Xenopus egg uroplakin III, an egg raft-associated transmembrane protein that is tyrosine-phosphorylated upon fertilization. J Biol Chem (2005) 1.12
Structural basis of urothelial permeability barrier function as revealed by Cryo-EM studies of the 16 nm uroplakin particle. J Cell Sci (2003) 1.08
Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis. Am J Physiol Renal Physiol (2006) 0.99
Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder. BMC Urol (2005) 0.96
Characterization of tight junction proteins in cultured human urothelial cells. In Vitro Cell Dev Biol Anim (2008) 0.95
Characterization of Xenopus egg membrane microdomains containing uroplakin Ib/III complex: roles of their molecular interactions for subcellular localization and signal transduction. Genes Cells (2007) 0.94
Uroplakin III, a novel Src substrate in Xenopus egg rafts, is a target for sperm protease essential for fertilization. Dev Biol (2005) 0.93
Induction of the urothelial differentiation program in the absence of stromal cues. J Urol (2005) 0.87
Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. Urology (2001) 0.82
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis (2011) 12.29
Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis (2010) 6.70
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med (2004) 2.82
CLINICAL PRACTICE. Urinary Tract Infections in Older Men. N Engl J Med (2016) 2.76
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med (2008) 2.66
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Delayed primary closure of bladder exstrophy: immediate postoperative management leading to successful outcomes. Urology (2011) 2.26
Brain functional and anatomical changes in chronic prostatitis/chronic pelvic pain syndrome. J Urol (2011) 2.08
Uropathogenic Escherichia coli induces chronic pelvic pain. Infect Immun (2010) 1.72
How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol (2006) 1.68
Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol (2003) 1.66
Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol (2003) 1.62
The MAPP research network: design, patient characterization and operations. BMC Urol (2014) 1.56
Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Arch Intern Med (2010) 1.55
Th1-Th17 cells contribute to the development of uropathogenic Escherichia coli-induced chronic pelvic pain. PLoS One (2013) 1.53
Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog (2009) 1.53
Molecular effects of genistein on male urethral development. J Urol (2011) 1.51
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol (2014) 1.47
Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators. J Urol (2010) 1.46
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol (2015) 1.45
Data mining derived treatment algorithms from the electronic medical record improve theoretical empirical therapy for outpatient urinary tract infections. J Urol (2011) 1.44
Host-pathogen interactions mediating pain of urinary tract infection. J Infect Dis (2010) 1.44
Prostatitis/chronic pelvic pain syndrome. Annu Rev Med (2006) 1.44
Mechanisms of pain from urinary tract infection. Int J Urol (2014) 1.43
Mast cell-derived histamine mediates cystitis pain. PLoS One (2008) 1.40
Ca(2+)/calmodulin-dependent protein kinase II is associated with pelvic pain of neurogenic cystitis. Am J Physiol Renal Physiol (2012) 1.40
Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol (2008) 1.39
The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate (2008) 1.38
Urinary tract infections in women. Med Clin North Am (2011) 1.34
Organ cross talk modulates pelvic pain. Am J Physiol Regul Integr Comp Physiol (2007) 1.33
Antigen-specific responses accelerate bacterial clearance in the bladder. J Immunol (2006) 1.32
Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli. Infect Immun (2007) 1.29
Experimental autoimmune prostatitis induces chronic pelvic pain. Am J Physiol Regul Integr Comp Physiol (2008) 1.28
Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin North Am (2007) 1.24
Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect Immun (2009) 1.24
Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. J Pain (2006) 1.22
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology (2002) 1.21
Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology (2006) 1.20
Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder. Infect Immun (2008) 1.17
Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy. J Urol (2013) 1.17
Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect Immun (2006) 1.15
Angiosarcoma of bladder: long-term survival after multimodal therapy. Urology (2007) 1.12
Psychosocial variables affect the quality of life of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome. BJU Int (2007) 1.10
Role of mast cells in male chronic pelvic pain. J Urol (2012) 1.07
Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-alpha. J Urol (2002) 1.06
Effect of prostate weight on operative and postoperative outcomes of robotic-assisted laparoscopic prostatectomy. Urology (2007) 1.06
Epithelial differentiation promotes the adherence of type 1-piliated Escherichia coli to human vaginal cells. J Infect Dis (2002) 1.06
Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis. J Urol (2006) 1.02
RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal Physiol (2007) 1.01
Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis. Am J Physiol Renal Physiol (2006) 0.99
CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am J Physiol Regul Integr Comp Physiol (2012) 0.96
A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis (2009) 0.96
Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents (2008) 0.95
Residual urine in an elderly female population: novel implications for oral estrogen replacement and impact on recurrent urinary tract infection. J Urol (2004) 0.95
Characterization of tight junction proteins in cultured human urothelial cells. In Vitro Cell Dev Biol Anim (2008) 0.95
Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol (2005) 0.93
Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis. BMC Urol (2009) 0.93
Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am (2003) 0.92
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91
O-antigen modulates infection-induced pain states. PLoS One (2012) 0.89
Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol (2006) 0.89
miR-199a-5p regulates urothelial permeability and may play a role in bladder pain syndrome. Am J Pathol (2012) 0.87
Induction of the urothelial differentiation program in the absence of stromal cues. J Urol (2005) 0.87
Acute and chronic prostatitis. Med Clin North Am (2004) 0.86
PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo. J Immunol (2011) 0.85
Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Curr Urol Rep (2008) 0.84
Role of bacteria in chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep (2005) 0.84
Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Curr Opin Infect Dis (2015) 0.84
The expanding role of fluoroquinolones. Dis Mon (2003) 0.83
Gender specific pelvic pain severity in neurogenic cystitis. J Urol (2011) 0.82
Epidemiologic insights into pediatric kidney stone disease. Urol Res (2010) 0.82
Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders. Am J Physiol Renal Physiol (2008) 0.82
Chronic bacterial prostatitis and chronic pelvic pain syndrome. BMJ Clin Evid (2015) 0.81
Is it time to change the training of urology residents in the United States? J Urol (2005) 0.81
Long-term results of the bulbourethral sling procedure. J Urol (2005) 0.80
Infectious response to E. coli: molecular and genetic pathways. Int J Antimicrob Agents (2004) 0.79
The role of cytokines in prostatitis. World J Urol (2003) 0.79
Durability of flexible cystoscopes in the outpatient setting. Urology (2013) 0.79
Genitourinary pain syndromes, prostatitis, and lower urinary tract symptoms. Urol Clin North Am (2009) 0.79
Evaluation of the cytokines in genital secretions of patients with chronic prostatitis. J Urol (2005) 0.79
Significant clinical practice cost savings through downsizing office supply inventory and just in time ordering. J Urol (2006) 0.78